Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2008

NicOx to Receive €3M in Funding through One-Year Extension of Opthamology Deal with Pfizer

  • NicOx and Pfizer agreed to a one-year extension of a March 2006 ophthalmology collaboration. Pfizer thus will continue to have exclusively rights to apply NicOx’ nitric oxide-donating technology to drug discovery research in the field of ophthalmology.

    NicOx will receive 3 million in research funding in March 2008. Additionally, Pfizer now has the option to obtain an exclusive, worldwide license to develop and commercialize compounds resulting from the research program until May 2009.

    The agreement provides for total potential milestone payments in excess of 300 million. This amount includes 102 million that would arise from the successful development and launch of the first compound.

    Encouraging results have been observed for various compounds in in vitro and in vivo preclinical models of a prevalent eye disease, according to the firms.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »